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At the beginning of the twentieth century, Ehrlich intro- 
duced the concept of"horror autotoxicus." He argued that 
the immune system was prevented from mounting an at- 
tack against the tissues it was designed to protect. At mid- 
century, Burnet formulated his clonal selection theory, 
which assumed that self-reactive lymphocytes were elimi- 
nated. We now know that autoreactive T and B cells can 
be readily detected, even in healthy individuals. Potent 
regulatory mechanisms that keep these cells in check 
have been discovered. When these controls fail, autoim- 
mune disease ensues. Of adults in Europe and North 
America, 5% (more than two thirds of them women) suffer 
from autoimmune diseases. Fortunately, our understand- 
ing of the pathogenesis of these diseases is increasing 
rapidly, and elegant strategies for treatment are being 
tested in the clinic. 
The Natural Occurrence of Autoreactive T Cells: 
Passing through Thymic Selection 
Many, but not all, self-reactive T cells are eliminated by 
negative selection in the thymus. In the process of nega- 
tive selection, self-reactive T cells die when they encounter 
self-antigen in the thymus. However, autoreactive T cells 
that have escaped thymic selection are not exceptional 
(Pette et al,, 1990), In healthy individuals, self-tolerance 
is thus maintained in part through mechanisms acting out- 
side the thymus that keep these autoreactive lymphocytes 
under control. It was thought hat self-reactive cells may 
escape negative selection because the self-antigen is not 
expressed in the thymus. However, there are two well- 
characterized circumstances in which self-antigens that 
are expressed in the thymus are recognized by T cells 
that migrate to the periphery. Myelin basic protein (MBP) 
and acetylcholine receptor (AChR) are present in the thy- 
mus during development of the immune system (Pribyl et 
al., 1993), and T cells with specificity for these antigens 
are detectable in the blood of normal laboratory animals 
and healthy humans. However, sometimes the mecha- 
nisms that keep these autoreactive T cells under control 
fail. Several factors can contribute to such failure, includ- 
ing the inheritance of certain genetic alleles and exposure 
to certain pathogens. 
Genes Conferring Susceptibility 
to Autoimmune Disease 
Susceptibility to several autoimmune diseases is linked 
to the major histocompatability compex (M HC) class II H LA 
genes. Perhaps the two clearest examples of HLA class II 
associations with disease are seen with insulin-dependent 
diabetes mellitus (IDDM) and pemphigus vulgaris (PV). In 
1987 McDevitt, Todd, and Bell, as well as Ehrlich indepen- 
dently, observed that resistance to IDDM correlates with 
the presence of the amino acid aepartate at postition 57 
of the HLA-DQ molecule. In contrast, HLA-DQ~ chains 
with serine, alanine, or valine at position 57 are associated 
with an increased risk of IDDM (Nepom and Ehrlich, 1991). 
In PV, a unique HLA-DQJ3 allele, differing from closely 
related alleles at position 57, was found exclusively in pa- 
tients with PV. The crystal structure of HLA class II illumi- 
nates the importance of residue 57, which is situated at 
one side of the HLA-binding groove. Only certain autoanti- 
gens bearing a specific characteristic net charge, appro- 
priate size, and hydrophilicity would be accommodated in 
the groove when particular amino acids are situated at 
position 57. Moreover, position 57 is aligned to interact 
with amino acids in the a chain. The influence of certain 
DQ~ and DQI~ sequences in combination promotes sus- 
ceptibility or resistance to IDDM and PV. 
Several genes outside the MHC influence the develop- 
ment of autoimmune disease. Susceptibility to IDDM has 
been linked to at least seven distinct loci in humans (Da- 
vies et al., 1994), with MHC class II having the strongest 
influence. In NOD mice, which develop IDDM spontane- 
ously, susceptibility is associated with several genes, 
though MHC class II has the strongest linkage. One gene 
conferring susceptibility to IDDM, named bcg, determines 
resistance or susceptibility to infectious diseases, includ- 
ing Leishmania, Salmonella, and tuberculosis (Cornall et 
al., 1991). The interaction of disease susceptibility genes 
and environmental factors is critical in autoimmune disease. 
A Role for Microbes in the A utoimmune Response 
Microbial superantigens trigger clinical relapses in autoim- 
mune disease. In experimental autoimmune ncephalo- 
myelitis (EAE), T cells expressing V~8 T cell receptors 
(TCRs) engage a fragment of MBP, leading to demyelin- 
ation and paralysis. The bacterial superantigen staphylo- 
coccal enterotoxin B activates VI38-expressing T cells. It 
had been assumed that antigens such as MBP were "pro- 
tected" from the immune system by virtue of their predomi- 
nant expression in the central nervous system, which is 
separated in part from the immune system by the blood- 
brain barrier. However, T cells that are exposed to MBP 
in the thymus and that are then activated by exogenous 
factors (like microbial superantigen) traverse the blood- 
brain barrier and thus may encounter MBP at the site of 
disease, where they can induce clinical relapses. Micro- 
bial activation of autoreactive T cells may be a widespread 
phenomenon responsible for the relapsing-remitting na- 
ture of many autoimmune diseases. Marrack has pro- 
posed a mechanism for the pathogenesis of rheumatoid 
arthritis (RA) in which an unknown superantigen activates 
disease-mediating T cells and allows these activated cells 
to enter the synovial tissue, where they persist because 
of reactivation by autoantigens (Paliard et al., 1991). A 
superantigen associated with pancreatic islets may be in- 
volved in the pathogenesis of IDDM (Conrad et al., 1994). 
The significance of infectious pathogens in autoimmu- 
nity was demonstrated in two genetically engineered 
strains of mice. I nterleukin-2 (IL-2) knockout mice develop 
inflammatory bowel disease, resembling ulcerative colitis, 
though the inflammatory bowel disease is not seen in 
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Table 1. Self-Antigens That Trigger Autoimmune Disease 
Disease Self-Antigen Proof 
MG AChR Conclusive 
Graves' disease TSH receptor Conclusive 
PV Desmoglein I Conclusive 
Stiff-man syndrome GAD Conclusive 
LEMS Synaptotagmin voltage-gated calcium channels Conclusive 
Isaac's syndrome Voltage-gated potassium channels Conclusive 
Paraneoplastic encephalitis RNA-binding protein HuD Conclusive 
MS MBP Strong 
IDDM GAD and heat shock protein Strong 
Primary biliary chirrhosis Dihydrolipoamide acetyltransferase Strong 
Scleroderma Topoisomerase I Strong 
Uveitis Interphotoreceptor retinoid-binding protein and S antigen Strong 
or rod outer segment 
There are three ways to prove conclusively that an immune response to an antigen causes autoimmune disease. First, if removal of the antibody 
or the T cells reacting to the antigen cures the disease, then it is reasonable to conclude that the antibody or T cells cause the disease. Next, if 
transfer of either specific antibody or antigen-specific T cells recapitulates the disease in an experimental nimal, then again one could conclude 
that the antibody or T cell is the cause of the autoimmune disease. Finally, in certain autoimmune diseases (including MG, Graves' disease, PV, 
LEMS, Isaac's yndrome, and stiff-man syndrome), ithas been possible to transfer the puta'dve disease-causing antibody from human to experimental 
animal and to recapitulate he disease. 
germ-free conditions (Sadlack et al., 1993). In a second 
example, in transgenic mice that express a TCR specific 
for MBP, EAE develops spontaneously, but the incidence 
is very low when these mice are raised in nonspecific 
pathogen-free conditions. Infection increases penetrance 
of the disease (Goverman et al., 1993). 
Another way in which pathogens contribute to autoim- 
munity is through molecular mimicry, which refers to struc- 
tural homologies between a self-protein and a protein in a 
viral or bacterial pathogen. Structural similarities between 
infectious pathogens and self-antigens may lead, in the 
course of an immune response to a pathogen, to inad- 
vertant autosensitization. For example, MBP shares ex- 
tensive homologies at the amino acid level with proteins 
from a number of common pathogens, including measles 
and hepatitis B. Rabbits developed EAE when immunized 
with a peptide sequence from hepatitis B with homology 
to MBP (Fujinami and OIdstone, 1985). Homology may be 
necessary at only a few of the amino acids comprising 
a T cell epitope: conservation of the native amino acid 
sequence at only 4 of 11 amino acids of an MBP epitope 
is sufficient to induce EAE. 
Self-Antigens That Trigger Autoimmune Disease 
For most autoimmune diseases, the specific self-antigen 
that triggers the immune system is unknown. For such 
conditions as systemic lupus erythematosus (SLE), Sjo- 
gren's syndrome, RA, and polymyositis, a strong candi- 
date for a particular antigen involved in pathogenesis has 
not yet emerged from a wide group of T cell and autoanti- 
body responses that are detected. The few diseases for 
which we know or suspect the identity of the the self- 
antigen that elicits the autoimmune response are listed in 
Table 1. 
Three of the diseases for which we know the identity of 
the self-antigen are autoimmune diseases at the neuro- 
muscular junction. A breakdown in the regulation of T and 
B cell tolerance to AChR leads to myasthenia gravis (MG). 
Antibody to AChR causes MG: infants of myasthenic moth- 
ers develop transient myasthenia from the transfer of anti- 
AChR immunoglobulin G (IgG) across the placenta. Plas- 
mapheresis ameliorates the symptoms of myasthenia as 
the anti-AChR titers are lowered, while thymectomy often 
cures the disease. Anti-AChR antibodies from humans can 
transfer the disease to mice. Another autoimmune disease 
of the neuromuscular junction, the Lambert-Eaton myas- 
thenic syndrome (LEMS), illuminates a fascinating interac- 
tion between cancer cells and the the immune system. 
This disease is characterized by proximal muscle weak- 
ness and autonomic dysfunction, including dry mouth and 
impotence. Most patients with this disease have small-cell 
lung cancer. LEMS patients make an antibody to an anti- 
gen on these cancer cells that is cross-reactive with synap- 
totagmin, found at neuromuscular junctions. Isaac's syn- 
drome (acquired neuromyotonia) is a third autoimmune 
disease of the neuromusular junction. Like LEMS, Isaac's 
syndrome is also associated with cancer, and patients uf- 
fer from continuous muscle contraction and excessive 
sweating. Autoantibodies are directed to voltage-gated po- 
tassium channels (Vincent and Newsom-Davis, 1994). 
Blister formation of the skin and mucous membranes, 
which can be life threatening, are the clinical manifesta- 
tions of PV. PV is mediated by antibodies that interfere 
with cell-to-ce! I contact of keratinocytes. The disease can 
be transferred to experimental animals by the immuno- 
globulins purified from patients. The autoantibodies in this 
disease target a keratinocyte surface protein, desmo- 
glein I, a member of the cadherin family of cell adhesion 
molecules (Amagai et al., 1991). 
Multiple sclerosis (MS) is a chronic disease involving an 
inflammatory reaction within the white matter of the central 
nervous system mediated by T cells, B cells, and macro- 
phages. The target of the inflammatory response in MS 
has been elusive. Analysis of the TCR gene rearrangements 
in the MS lesion has indicated that there are a restricted 
group of CDR3 motifs (Oksenberg et al., 1993) that are 
identical to those found in several human and rodent T 
cell clones reactive to MBP peptides 87-99. The B cell 
response to MBP in MS has also been studied extensively. 
Of 116 chronic progressive MS patients, 111 had anti-MBP 
titers in the cerebrospinal fluid (CSF), while 173 of 180 
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relapsing MS patients had anti-MBP antibody in the CSF. 
Most of the patients who had no anti-MBP antibody in the 
CSF did have antibody to proteolipid protein of myelin. IgG 
purified from brain lesions reacted with the same region of 
MBP, p75-106, that is the immunodominant T cell epitope 
in MS (Warren et al., 1994). Taken together, these data 
indicate that a cellular and humoral immune response to 
this region of MBP may be critical in MS. Although antibod- 
ies to myelin oligodendroglial glycoprotein and proteolipid 
protein are also found in the CSF of some MS patients, 
the major response in 90% of patients is directed to MBP. 
In IDDM, 80% of patients have antibodies to GAD65 (glu- 
tamic acid decarboxylase). GAD6s is the initial antigen at- 
tacked in NOD mice, and tolerization to this antigen in 
young mice prevents diabetes (Kaufman et al., 1993; Tisch 
et al., 1993). Another autoimmune disease, stiff-man syn- 
drome, is associated with an autoimmune response to 
GAD6~. In this disease, stiffness of muscles and painful 
spasms are related toa defect in the metabolism of the 
neurotransmitter 7-amino butyric acid. One third of pa- 
tients with stiff-man syndrome have IDDM as well (Kim et 
al., 1994). 
After an Initial Response to Self, the Autoimmune 
Repertoire Expands: The Concept of 
Determinant Spreading 
The target of attack remains enigmatic in most autoim- 
mune diseases. One of the problems in identifying the 
antigens that trigger these diseases is that after the initial 
autoimmune response, there is a diversification of the T 
and B cell responses to other antigens at the site of inflam- 
mation. This concept has been named °determinant spread- 
ing" by Sercarz and colleagues. Determinant spreading 
was first demonstrated in EAE and then in spontaneous 
insulin-dependent diabetes in the NOD mouse (Kaufman 
et al., 1993; Tisch et al., 1993). Determinant spreading 
reflects a chain of immune responses. Initially, the immune 
response is directed to a peptide epitope on the inciting 
antigen. The response then spreads to other peptide epi- 
topes on the same protein (intramolecular spreading) and 
then to different epitopes on different proteins (intermolec- 
ular spreading) within the target tissue. 
In the NOD model of IDDM, the T cell response was 
initially confined to a limited region of GAD. The response 
then spread to additional determinants of GAD and then 
to other antigens, including heat shock proteins expressed 
in the pancreatic 13 cells. The importance of other antigens, 
especially HSP60, in the pathogenesis of IDDM has been 
established. Tolerization to HSP60 leads to reversal of 
diabetes in NOD mice (Elias and Cohen, 1994). 
Both intramolecular and intermolecular determinant 
spreading has been demonstrated in many other autoim- 
mune diseases. In MG, both the T and B cell responses 
targetmultiple regions on AChR, indicating intramolecular 
spread. Stimulatory autoantibodies directed to certain epi- 
topes on the TSH receptor elicit hyperthyroidism in Graves' 
disease, while blocking antibodies to other epitopes on 
the TSH receptor cause primary autoimmune myxedema. 
In Graves' disease, T cell clones isolated from the inflam- 
matory thyroid infiltrates revealed reactivity to several de- 
terminants on thyroid peroxidase, suggesting intermolec- 
ular determinant spreading from TSH receptor. In primary 
biliary cirrhosis, autoantibodies are directed against a 
wide family of branched chain keto acid dehydrogenase 
complexes, indicating intermolecular determinant spread- 
ing. In scleroderma patients, a pathogenic autoantibody 
directed to topoisomerase I has been detected that recog- 
nizes a cross-reactive pitope in the tight skin mouse (Mur- 
yoi et al., 1992). Also seen in scleroderma are autoantibod- 
ies against RNA polymerase transcription factors and 
other targets in the nucleolus organizer region, indicating 
intermolecular spreading. 
T Cells, Cytokines, and Adhesion Molecules 
in the Regulation of Autoimmunity 
Genetic engineering of mice has been useful in elucidating 
the action of particular genes in the development of auto- 
immunity. An important role for the CD8 coreceptor on T 
cells in clinical remission of EAE was demonstrated using 
CD8 + mice: relapses of disease were more common for 
CD8 -j- mice than for CD8 +~+ mice (Koh et al., 1992). That 
some T cells protect against autoimmunity was also dem- 
onstrated by Lafaille and colleagues, who developed 
transgenic mice with a TCR for MBP and crossed them 
to RAGl-deficient mice (mice deficient in the ability to re- 
arrange TCR). Only 14% of the TCR transgenic mice who 
were RAG1 + developed EAE, while 100% of the TCR 
transgenic mice who were RAG1- developed disease. 
Thus, the nontransgenic !ymphocytes protected against 
disease, and clarification of their identity is underway (La- 
faille et al., 1994). 
Some cytokines appear to protect against autoimmune 
disease whereas others promote disease. Transforming 
growth factor 131 (TGFI31) knockout mice had inflammatory 
lesions in heart, liver, and lungs, indicating that TGFI31 is 
a critical anti-inflammatory cytokine (Shull et al., 1992). 
IL-10 knockout mice developed chronic enterocolitis 
(Kuhn et al., 1993). MRL/Ipr and gld mice, defective in fas 
and fas ligand, respectively, manifest many of the features 
of SLE in humans, including glomerulonephritis, vasculi- 
tis, and a broad array of autoantibodies. Since fas, a mem- 
ber of the tumor necrosis factor (TNF) receptor family, 
normally transduces an apoptotic signal, these mice dem- 
onstrate a connection between aberrantly regulated apop- 
tosis and autoimmune disease (Takahashi et al., 1994). 
Although the above examples all show that loss of cytokine 
signals leads to autoimmunity, aberrant cytokine expres- 
sion can also cause an autoimmune response. For exam- 
ple, transgenic mice expressing TNF~ develop spontane- 
ous inflammatory arthritis. 
Different ypes of T cells secrete different ypes of cyto- 
kines, which have different effects on the immune re- 
sponse. Cytokines themselves have been used effectively 
to treat disease in animal models. IDDM in the NOD 
mouse, as well as EAE, can be triggered with T lympho- 
cytes bearing aThl  phenotype, which produces iL-2, inter- 
feron-y, and TNF. Th2 iymphocytes produce IL-10 and 
I L-4. This has stimulated strategies to treat diseases medi- 
ated by Thl T cells, with cytokines produced by Th2 cells. 
In NOD mice, IL-4 replacement in vivo prevents IDDM 
(Rapoport et al., 1993). In EAE, administration of IL-4 pre- 
vents the transfer of disease with T cells reactive to MBP. 
Weiner et al. have isolated T suppressor cells specific for 
MBP that produce !L-4, IL-lO, and TGF6 and that prevent 
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EAE, even when induced with proteolipid protein of myelin. 
This nonspecific suppressor mechanism is named inno- 
cent bystander suppression (Weiner et al., 1994). 
Adhesion molecules have a selective role in the homing 
of lymphocytes to different anatomic sites. In models of 
diabetes in the NOD mouse and in EAE, disease can be 
reversed with antibodies to ~4 integrin (Steinman, 1993). 
While (~4 integrin is involved in homing to pancreatic islets 
and the central nervous system, these molecules are not 
involved in lymphocyte homing to the inflamed salivary 
glands seen in the NOD mouse. L-selectin is involved in 
homing to pancreatic islets, but plays no role in the devel- 
opment of acute EAE lesions. Thus, different adhesion 
molecules are involved in homing to different target or- 
gans, and this specificity may be exploited therapeutically. 
Therapeutic Intervention to Restore Self.Tolerance 
A number of approaches aimed at restoring self-tolerance 
in autoimmune disease are now being implemented in clin- 
ical trials in humans (reviewed by Steinman, 1993). Some 
of these trials involve targeting molecules involved in the 
interaction among T cells, MHC, and self-peptide (Gaur 
and Fathman, 1994). For example, patients with various 
autoimmune diseases have been treated with humanized 
monoclonal antibodies to CD4 and to CDw52. Patients 
with MS have been immunized against the CDR2 compo- 
nent of a TCR V region recognizing MBP. Relapsing-remit- 
ting MS has been successfully treated by blocking antigen 
interaction with MHC with a copolymer resembling MBP, 
termed COP1. Attempts to induce tolerance by feeding 
antigen have given encouraging results in small trials with 
MS patients and in RA (Weiner et al., 1994). 
Interferon-~ is now approved by the Food and Drug Ad- 
ministration for clinical use in MS patients for treatment 
of relapsing-remitting MS. This cytokine may act by down- 
regulating the expression of interferon-~, and TNF in the 
MS lesion (reviewed by Steinman, 1993). Blockade of 
TNFa with a monoclonal antibody has given promising 
results in trials for treatment of chronic RA and for treat- 
ment of exacerbations of inflammatory bowel disease (EI- 
liott et al., 1993). TGFI5 trials are in progress for treatment 
of MS. Other approaches, including blockade of adhesion 
molecules involved in lymphocyte homing, are underway 
for treatment of MS and RA. The investment in research 
on the pathogenesis of autoimmunity is beginning to pay 
dividends. Prevention and treatments for many of these 
diseases may be available in the foreseeable future. 
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